ASH 2023 | KT-333: a first-in-class STAT3 degrader
Aditi Shastri, MD, Montefiore Medical Center, Bronx, NY, discusses the preliminary data of an ongoing Phase Ia/Ib trial (NCT05225584) investigating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of KT-333. This agent is a first-in-class targeted degrader of the signal transducer and activator of transcription 3 (STAT3) protein, which is mutated or deregulated in several hematological malignancies and solid tumors. At present, efficacy data are not yet available, but safety data show a favorable safety profile of the drug. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Gilead Sciences, Rigel Pharmaceuticals, Kymera Therapeutics, Janssen Pharmaceuticals, Inc.
Research Funding: Kymera Therapeutics
Consultancy: Janssen Pharmaceuticals, Inc.
